Kite scores a land­mark win with promis­ing 6-month lym­phoma da­ta for lead CAR-T

Kite Phar­ma’s close­ly-watched lead CAR-T turned in pos­i­tive six-month re­sults for ag­gres­sive non-Hodgkin lym­phoma, hit­ting a key goal as the biotech rolls up to the FDA with its ap­pli­ca­tion for mar­ket­ing ap­proval.

A group of skep­tics had lashed the com­pa­ny af­ter its three-month re­sults, which demon­strat­ed a clus­ter of re­laps­es and a sharp drop in ob­jec­tive re­sponse rates and com­plete re­spons­es for axi­cab­ta­gene ciloleu­cel (KTE-C19). But CEO Arie Bellde­grun told me last fall that in­ves­ti­ga­tors be­lieved that the six-month re­sults would show that the ef­fi­ca­cy plateaued, demon­strat­ing its dura­bil­i­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.